Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial

October 20, 2022

https://www.globenewswire.com/news-release/2022/10/20/2538153/0/en/Talaris-Therapeutics-Provides-Update-on-FREEDOM-1-Phase-3-Clinical-Trial.html

BOSTON and LOUISVILLE, Ky., Oct. 20, 2022 (GLOBE NEWSWIRE) — Talaris Therapeutics, Inc. (Nasdaq:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced a status update on its Phase 3 FREEDOM-1 study in living donor kidney transplant (LDKT) recipients.

Read more at globenewswire.com

Related news for (TALS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.